Innovation
Limited to unlimited
Innovation
Innovation is one of the fundamental values
in our business. Field of medical and
pharmaceutical is full of next generation
where innovation is the key to be in this
game. At CHAEUM PHARMA, we push
the limits of knowledge to discover the
tradition to be new approach,
limited to unlimited.
Innovation
Intensive R&D
Our creativity originated from our stubbornness
to sustain the pure sources at high standard.
Every single material is rigidly selected by years of studies and scientific discover under strict disciplines.
With the acceleration of new technologies, CHAEUM PHARMA is increasing its capacity for innovation to create and develop ever more personalized and inclusive products, services and natural experiences.
Innovation
Manufacturing
Excellence is our guide.
We are in a constant quest to offer the best. All our manufacturing facilities are under the highly selected standard
to maintain the quality that has been proven by years. Consistency is a key to carry out the best quality in global market.
Four manufacturing facilities are environmentally controlled in 3 different continents, under 42 qualification including ISO, GMP, KGMP, FDA, CFDA, ANVISA, MDSAP, CE(EC), etc, which applied to each facility under strict condition to fulfill human-environmental familiar system.
Safety and quality record.
In accordance with medical standard, all product under UDI&EAN system are traceable which allow us carry
out the market surveillance and keep the safety-quality measure. Safety and quality are essential pillars of our
business conduct, and key to our long-trusted relationships with consumers, patients and healthcare professionals.
Our quality and manufacturing processes adhere to a number of local and global laws and regulations.
Project California
This is new concept of agile factory to reinforce abandoned
factory since 1980s as a part of ‘encouraging employment’
and ‘renovation of outskirt of city of beauty.’
New ‘Project California’ is strategic outpoint for US market by 3rd quarter of 2024. Invested and governed by CHAEUM GROUP INC. managed by CHAEUM PHARMA.